Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: Results after 1 year from a prospective, observational study (IC-SOHO)

Tamás Treuer, Martin Anders, I. Bitter, Gheorghe Dobre, Jan Pecenak, Yulia Dyachkova, Gavan Harrison, John O'Mahoney

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective. The Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study is intended to complement smaller, shorter-term observational studies and randomised controlled clinical trials in providing information on the treatment of schizophrenia in various geographies that have not been well studied previously. Methods. Interim results after 12 months are presented for a subset of patients from eight Central and Eastern European (CEE) countries initiating or switching to olanzapine, risperidone, or typical antipsychotic monotherapy at Baseline ( n =1387). Results. Patients initially prescribed olanzapine and risperidone experienced significantly greater improvements in a broad range of schizophrenia symptom domains compared with patients prescribed typicals. Furthermore, patients in the olanzapine group showed significantly greater improvements in overall and negative symptom domains compared with the risperidone group (all P ≤0.05). While patients in the olanzapine group gained more weight than the other two groups, they had significantly lower odds of developing extrapyramidal symptoms, loss of libido, and sexual dysfunction. Patients initially prescribed olanzapine were also significantly less likely to have changed or added antipsychotics during 12 months of treatment compared with the risperidone and typicals groups. Conclusion. In this CEE sample, schizophrenia treatment outcomes after 12 months varied between patients initially prescribed different antipsychotics.

Original languageEnglish
Pages (from-to)78-90
Number of pages13
JournalInternational Journal of Psychiatry in Clinical Practice
Volume10
Issue number2
DOIs
Publication statusPublished - Jun 2006

Fingerprint

olanzapine
Eastern Europe
Observational Studies
Schizophrenia
Outpatients
Prospective Studies
Risperidone
Health
Antipsychotic Agents
Therapeutics
Libido
Geography
Randomized Controlled Trials
Outcome Assessment (Health Care)
Weights and Measures

Keywords

  • Observational study
  • Olanzapine
  • Risperidone
  • Schizophrenia
  • Typical antipsychotics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe : Results after 1 year from a prospective, observational study (IC-SOHO). / Treuer, Tamás; Anders, Martin; Bitter, I.; Dobre, Gheorghe; Pecenak, Jan; Dyachkova, Yulia; Harrison, Gavan; O'Mahoney, John.

In: International Journal of Psychiatry in Clinical Practice, Vol. 10, No. 2, 06.2006, p. 78-90.

Research output: Contribution to journalArticle

Treuer, Tamás ; Anders, Martin ; Bitter, I. ; Dobre, Gheorghe ; Pecenak, Jan ; Dyachkova, Yulia ; Harrison, Gavan ; O'Mahoney, John. / Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe : Results after 1 year from a prospective, observational study (IC-SOHO). In: International Journal of Psychiatry in Clinical Practice. 2006 ; Vol. 10, No. 2. pp. 78-90.
@article{a822a60558564a12b7b39090bc79aa56,
title = "Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: Results after 1 year from a prospective, observational study (IC-SOHO)",
abstract = "Objective. The Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study is intended to complement smaller, shorter-term observational studies and randomised controlled clinical trials in providing information on the treatment of schizophrenia in various geographies that have not been well studied previously. Methods. Interim results after 12 months are presented for a subset of patients from eight Central and Eastern European (CEE) countries initiating or switching to olanzapine, risperidone, or typical antipsychotic monotherapy at Baseline ( n =1387). Results. Patients initially prescribed olanzapine and risperidone experienced significantly greater improvements in a broad range of schizophrenia symptom domains compared with patients prescribed typicals. Furthermore, patients in the olanzapine group showed significantly greater improvements in overall and negative symptom domains compared with the risperidone group (all P ≤0.05). While patients in the olanzapine group gained more weight than the other two groups, they had significantly lower odds of developing extrapyramidal symptoms, loss of libido, and sexual dysfunction. Patients initially prescribed olanzapine were also significantly less likely to have changed or added antipsychotics during 12 months of treatment compared with the risperidone and typicals groups. Conclusion. In this CEE sample, schizophrenia treatment outcomes after 12 months varied between patients initially prescribed different antipsychotics.",
keywords = "Observational study, Olanzapine, Risperidone, Schizophrenia, Typical antipsychotics",
author = "Tam{\'a}s Treuer and Martin Anders and I. Bitter and Gheorghe Dobre and Jan Pecenak and Yulia Dyachkova and Gavan Harrison and John O'Mahoney",
year = "2006",
month = "6",
doi = "10.1080/13651500500409663",
language = "English",
volume = "10",
pages = "78--90",
journal = "International Journal of Psychiatry in Clinical Practice",
issn = "1365-1501",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe

T2 - Results after 1 year from a prospective, observational study (IC-SOHO)

AU - Treuer, Tamás

AU - Anders, Martin

AU - Bitter, I.

AU - Dobre, Gheorghe

AU - Pecenak, Jan

AU - Dyachkova, Yulia

AU - Harrison, Gavan

AU - O'Mahoney, John

PY - 2006/6

Y1 - 2006/6

N2 - Objective. The Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study is intended to complement smaller, shorter-term observational studies and randomised controlled clinical trials in providing information on the treatment of schizophrenia in various geographies that have not been well studied previously. Methods. Interim results after 12 months are presented for a subset of patients from eight Central and Eastern European (CEE) countries initiating or switching to olanzapine, risperidone, or typical antipsychotic monotherapy at Baseline ( n =1387). Results. Patients initially prescribed olanzapine and risperidone experienced significantly greater improvements in a broad range of schizophrenia symptom domains compared with patients prescribed typicals. Furthermore, patients in the olanzapine group showed significantly greater improvements in overall and negative symptom domains compared with the risperidone group (all P ≤0.05). While patients in the olanzapine group gained more weight than the other two groups, they had significantly lower odds of developing extrapyramidal symptoms, loss of libido, and sexual dysfunction. Patients initially prescribed olanzapine were also significantly less likely to have changed or added antipsychotics during 12 months of treatment compared with the risperidone and typicals groups. Conclusion. In this CEE sample, schizophrenia treatment outcomes after 12 months varied between patients initially prescribed different antipsychotics.

AB - Objective. The Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study is intended to complement smaller, shorter-term observational studies and randomised controlled clinical trials in providing information on the treatment of schizophrenia in various geographies that have not been well studied previously. Methods. Interim results after 12 months are presented for a subset of patients from eight Central and Eastern European (CEE) countries initiating or switching to olanzapine, risperidone, or typical antipsychotic monotherapy at Baseline ( n =1387). Results. Patients initially prescribed olanzapine and risperidone experienced significantly greater improvements in a broad range of schizophrenia symptom domains compared with patients prescribed typicals. Furthermore, patients in the olanzapine group showed significantly greater improvements in overall and negative symptom domains compared with the risperidone group (all P ≤0.05). While patients in the olanzapine group gained more weight than the other two groups, they had significantly lower odds of developing extrapyramidal symptoms, loss of libido, and sexual dysfunction. Patients initially prescribed olanzapine were also significantly less likely to have changed or added antipsychotics during 12 months of treatment compared with the risperidone and typicals groups. Conclusion. In this CEE sample, schizophrenia treatment outcomes after 12 months varied between patients initially prescribed different antipsychotics.

KW - Observational study

KW - Olanzapine

KW - Risperidone

KW - Schizophrenia

KW - Typical antipsychotics

UR - http://www.scopus.com/inward/record.url?scp=33745075014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745075014&partnerID=8YFLogxK

U2 - 10.1080/13651500500409663

DO - 10.1080/13651500500409663

M3 - Article

AN - SCOPUS:33745075014

VL - 10

SP - 78

EP - 90

JO - International Journal of Psychiatry in Clinical Practice

JF - International Journal of Psychiatry in Clinical Practice

SN - 1365-1501

IS - 2

ER -